<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3318">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02092701</url>
  </required_header>
  <id_info>
    <org_study_id>HDB1</org_study_id>
    <nct_id>NCT02092701</nct_id>
  </id_info>
  <brief_title>Effects of Cholecalciferol Supplementation on Bone Health and Muscle Strength in Adults During Post-burn Period</brief_title>
  <official_title>Effects of a One Year Cholecalciferol Supplementation on Bone Health and Muscle Strength in Adults During Post-burn Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Liege</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D has pleiotropic effects. Burn patients are at risk of hypovitaminosis D and may
      experience post-injury osteopenia and sarcopenia. Investigators hypothesized that vitamin D
      supplementation during one year can improve bone and muscle health in post-burn period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>calcidiol blood concentration</measure>
    <time_frame>at the end of the protocol (after one year)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone health</measure>
    <time_frame>at the end of the protocol (after one year)</time_frame>
    <safety_issue>No</safety_issue>
    <description>bone formation and resorption markers (blood concentrations) bone mineral density measurement using dual energy X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle strength</measure>
    <time_frame>at the end of the protocol (after one year)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurements of knee muscles strength on an isokinetic dynamometer</description>
  </secondary_outcome>
  <condition>Vitamin D</condition>
  <condition>Burn Injury</condition>
  <arm_group>
    <arm_group_label>cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <arm_group_label>cholecalciferol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  occurrence of injury between 2005 and 2011

          -  burn surface area (BSA) greater than 10%

        Exclusion Criteria:

          -  Pregnancy, renal or liver failure, hypo or hyperparathyroidism, prior vitamin D
             substitution, treatment using systemic corticosteroids or antiepileptic drugs,
             regular exposure to ultraviolet B radiation (solarium), unstable cardiovascular
             disease or acute muscle or skeletal injury prohibiting physical exercise
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Burn Centre</name>
      <address>
        <city>Li√®ge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>March 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Liege</investigator_affiliation>
    <investigator_full_name>Rousseau</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Burns</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
